Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral Injection Alone and in Combination With Immune Checkpoint Blockade

NCT03739931 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT03739931
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03739931 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral Injection Alone and in Combination With Immune Checkpoint Blockade
Lead sponsor
ModernaTX, Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 27, 2018
Completion date
August 1, 2025
Enrollment
134 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

dose escalation: relapsed/refractory solid tumor malignancies or lymphoma, dose expansion: triple negative breast cancer, hnscc, non-hodgkins, urothelial cancer, immune checkpoint refractory melanoma, and nsclc lymphoma